TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Study of OMTX705 in Pancreatic Cancer
LUND, Sweden – TFS HealthScience, a leading global contract research organization (CRO), has announced an expanded collaboration with Oncomatryx, a biopharmaceutical firm specializing in the development of innovative antibody-drug conjugates (ADCs). This partnership is centered around a newly launched Phase Ib clinical study focusing on OMTX705—an ADC targeting the fibroblast activation protein (FAP-ADC)—in patients suffering from advanced or metastatic pancreatic adenocarcinoma. The study will take place at various sites across Spain and the United States.
According to the World Cancer Research Foundation, pancreatic cancer remains one of the deadliest malignancies worldwide, with over 510,000 new cases and more than 466,000 deaths each year. Despite advancements in oncology, treatment options for patients with advanced or metastatic disease are still limited, with a five-year survival rate lingering below 10%. This stark reality emphasizes the urgent need for new and more effective treatment alternatives.
The Phase Ib study represents a continuation of the collaboration between TFS and Oncomatryx that began during a previous Phase I study assessing OMTX705 both as a monotherapy and in combination with pembrolizumab for advanced solid tumors. The promising outcomes from this initial study have laid the groundwork for this next phase of development, showcasing the consistent performance and comprehensive therapeutic expertise that Oncomatryx values in its ongoing partnership with TFS.
"Our collaboration with Oncomatryx reflects our shared commitment to accelerating the development of innovative therapies for challenging cancers like pancreatic adenocarcinoma," said Kris O'Brien, Vice President and Head of the Oncology and Rare Diseases Division at TFS. "TFS contributes deep therapeutic insights and operational agility to every program we support, committing ourselves to advance promising science where it is needed most."
"We are entering an exciting new phase in the clinical development of OMTX705," notes Laureano Simón, CEO of Oncomatryx. "TFS has proven to be a trusted and competent partner—essential attributes in advancing our science for patients who urgently require new options."
With over two decades of experience in oncological research, TFS supports clinical trials addressing solid tumors, hematological malignancies, and rare cancers. By focusing on agility, scientific rigor, and global reach, TFS has successfully guided numerous oncology programs from concept to clinic in both early and late phases. Through long-standing partnerships, including the renewed cooperation with Oncomatryx, TFS continues to provide tailored clinical solutions, fostering scientific endeavors aimed at improving patients' quality of life worldwide.
The OMTX705 program is poised to gain momentum following a successful €25 million funding round concluded in late 2024, with clinical data from Phase I expected to be presented at major oncology conferences throughout 2025. This initiative is drawing increased attention as a promising new treatment approach for challenging tumors like pancreatic adenocarcinoma.
About TFS HealthScience: TFS HealthScience is a full-service global contract research organization (CRO) dedicated to advancing innovative treatments and improving patient outcomes in collaboration with biotechnology and pharmaceutical companies. Operating in 40 countries, TFS and its strategic partners offer customized solutions for strategic procurement and clinical development across specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. TFS is committed to empowering partners and enriching lives, providing flexible solutions that combine global reach with the responsiveness of a mid-sized CRO.
About Oncomatryx: Oncomatryx develops a proprietary antibody-drug conjugate platform targeting cancer-associated fibroblasts in the microenvironment of metastatic solid tumors. The groundbreaking ADCs from Oncomatryx against immunosuppressive tumors are being developed in collaboration with leading universities, hospitals, and research centers in the US and Europe. Clinical results from the Phase I trial of OMTX705, a novel ADC targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts, will be presented at leading oncology conferences in 2025.
According to the World Cancer Research Foundation, pancreatic cancer remains one of the deadliest malignancies worldwide, with over 510,000 new cases and more than 466,000 deaths each year. Despite advancements in oncology, treatment options for patients with advanced or metastatic disease are still limited, with a five-year survival rate lingering below 10%. This stark reality emphasizes the urgent need for new and more effective treatment alternatives.
The Phase Ib study represents a continuation of the collaboration between TFS and Oncomatryx that began during a previous Phase I study assessing OMTX705 both as a monotherapy and in combination with pembrolizumab for advanced solid tumors. The promising outcomes from this initial study have laid the groundwork for this next phase of development, showcasing the consistent performance and comprehensive therapeutic expertise that Oncomatryx values in its ongoing partnership with TFS.
"Our collaboration with Oncomatryx reflects our shared commitment to accelerating the development of innovative therapies for challenging cancers like pancreatic adenocarcinoma," said Kris O'Brien, Vice President and Head of the Oncology and Rare Diseases Division at TFS. "TFS contributes deep therapeutic insights and operational agility to every program we support, committing ourselves to advance promising science where it is needed most."
"We are entering an exciting new phase in the clinical development of OMTX705," notes Laureano Simón, CEO of Oncomatryx. "TFS has proven to be a trusted and competent partner—essential attributes in advancing our science for patients who urgently require new options."
With over two decades of experience in oncological research, TFS supports clinical trials addressing solid tumors, hematological malignancies, and rare cancers. By focusing on agility, scientific rigor, and global reach, TFS has successfully guided numerous oncology programs from concept to clinic in both early and late phases. Through long-standing partnerships, including the renewed cooperation with Oncomatryx, TFS continues to provide tailored clinical solutions, fostering scientific endeavors aimed at improving patients' quality of life worldwide.
The OMTX705 program is poised to gain momentum following a successful €25 million funding round concluded in late 2024, with clinical data from Phase I expected to be presented at major oncology conferences throughout 2025. This initiative is drawing increased attention as a promising new treatment approach for challenging tumors like pancreatic adenocarcinoma.
About TFS HealthScience: TFS HealthScience is a full-service global contract research organization (CRO) dedicated to advancing innovative treatments and improving patient outcomes in collaboration with biotechnology and pharmaceutical companies. Operating in 40 countries, TFS and its strategic partners offer customized solutions for strategic procurement and clinical development across specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. TFS is committed to empowering partners and enriching lives, providing flexible solutions that combine global reach with the responsiveness of a mid-sized CRO.
About Oncomatryx: Oncomatryx develops a proprietary antibody-drug conjugate platform targeting cancer-associated fibroblasts in the microenvironment of metastatic solid tumors. The groundbreaking ADCs from Oncomatryx against immunosuppressive tumors are being developed in collaboration with leading universities, hospitals, and research centers in the US and Europe. Clinical results from the Phase I trial of OMTX705, a novel ADC targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts, will be presented at leading oncology conferences in 2025.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.